ARGX.BR
Price:
$487.6
Market Cap:
$32.33B
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-...[Read more]
Industry
Biotechnology
IPO Date
2014-07-10
Stock Exchange
EURONEXT
Ticker
ARGX.BR
According to argenx SE’s latest financial reports and current stock price. The company's current PE Ratio is -154.30. This represents a change of 1.40% compared to the average of -10.30 of the last 4 quarters.
The mean historical PE Ratio of argenx SE over the last ten years is -29.78. The current -154.30 PE Ratio has changed 51.72% with respect to the historical average. Over the past ten years (40 quarters), ARGX.BR's PE Ratio was at its highest in in the June 2024 quarter at 206.15. The PE Ratio was at its lowest in in the June 2018 quarter at -469.38.
Average
-29.78
Median
-29.47
Minimum
-71.96
Maximum
-4.59
Discovering the peaks and valleys of argenx SE PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 195.63%
Maximum Annual PE Ratio = -4.59
Minimum Annual Increase = -68.69%
Minimum Annual PE Ratio = -71.96
Year | PE Ratio | Change |
---|---|---|
2023 | -71.96 | 151.95% |
2022 | -28.56 | -36.40% |
2021 | -44.90 | 165.82% |
2020 | -16.89 | -44.40% |
2019 | -30.38 | -18.67% |
2018 | -37.35 | -5.33% |
2017 | -39.45 | 195.63% |
2016 | -13.35 | 28.85% |
2015 | -10.36 | 125.75% |
2014 | -4.59 | -68.69% |
The current PE Ratio of argenx SE (ARGX.BR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-48.47
5-year avg
-38.54
10-year avg
-29.78
argenx SE’s PE Ratio is less than Galapagos NV (5.82), less than Mithra Pharmaceuticals SA (-0.09), less than UCB SA (126.91), less than Biocartis Group NV (-0.32), less than Melexis NV (14.88),
Company | PE Ratio | Market cap |
---|---|---|
5.82 | $1.65B | |
-0.09 | $14.93M | |
126.91 | $30.43B | |
-0.32 | $27.24M | |
14.88 | $3.10B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like argenx SE using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like argenx SE or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is argenx SE's PE Ratio?
How is the PE Ratio calculated for argenx SE (ARGX.BR)?
What is the highest PE Ratio for argenx SE (ARGX.BR)?
What is the 3-year average PE Ratio for argenx SE (ARGX.BR)?
What is the 5-year average PE Ratio for argenx SE (ARGX.BR)?
How does the current PE Ratio for argenx SE (ARGX.BR) compare to its historical average?